Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANVS Annovis Bio	$2.10 -3.4%	$2.16	$1.11 ▼ $17.88	$42.28M	1.62	754,054 shs	440,443 shs
CRGX CARGO Therapeutics	$4.19 -0.7%	$4.30	$3.00 ▼ $25.45	$194.59M	0.31	577,189 shs	610,988 shs
MNPR Monopar Therapeutics	$33.60 -4.0%	$36.75	$1.72 ▼ $54.30	$214.09M	0.99	360,287 shs	567,062 shs
YMAB Y-mAbs Therapeutics	$4.70 -2.1%	$4.46	$3.55 ▼ $16.11	$217.36M	0.52	305,221 shs	212,172 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANVS Annovis Bio	-3.19%	-19.75%	-13.39%	+27.42%	-63.42%
CRGX CARGO Therapeutics	-0.71%	-1.87%	+1.45%	+0.24%	-71.30%
MNPR Monopar Therapeutics	-4.03%	+2.25%	+3.51%	-16.69%	+801.41%
YMAB Y-mAbs Therapeutics	-2.08%	+6.58%	+1.73%	-2.29%	-60.93%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANVS Annovis Bio	2.1341 of 5 stars	3.5	1.0	2.5	1.7	0.6
CRGX CARGO Therapeutics	2.4819 of 5 stars	2.9	0.0	3.3	1.7	1.3
MNPR Monopar Therapeutics	3.0003 of 5 stars	3.4	5.0	2.1	2.5	0.0
YMAB Y-mAbs Therapeutics	2.9449 of 5 stars	4.4	1.0	1.6	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANVS Annovis Bio	3.00	Buy	$30.25	1,343.23% Upside
CRGX CARGO Therapeutics	1.86	Reduce	$15.00	258.00% Upside
MNPR Monopar Therapeutics	2.80	Moderate Buy	$56.50	68.15% Upside
YMAB Y-mAbs Therapeutics	2.82	Moderate Buy	$15.60	231.91% Upside

Current Analyst Ratings Breakdown

Latest ANVS, MNPR, YMAB, and CRGX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/23/2025	MNPR Monopar Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00
6/9/2025	ANVS Annovis Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $12.00
5/29/2025	YMAB Y-mAbs Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$20.00 ➝ $15.00
5/28/2025	YMAB Y-mAbs Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$21.00 ➝ $18.00
5/19/2025	YMAB Y-mAbs Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $11.00
5/15/2025	ANVS Annovis Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$26.00 ➝ $17.00
5/14/2025	YMAB Y-mAbs Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $14.00
5/14/2025	YMAB Y-mAbs Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$21.00 ➝ $20.00
4/22/2025	YMAB Y-mAbs Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Underperform	$3.00
4/2/2025	MNPR Monopar Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
4/1/2025	MNPR Monopar Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANVS Annovis Bio	N/A	N/A	N/A	N/A	$0.67 per share	N/A
CRGX CARGO Therapeutics	N/A	N/A	N/A	N/A	$7.83 per share	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	$9.02 per share	N/A
YMAB Y-mAbs Therapeutics	$87.68M	2.43	N/A	N/A	$2.05 per share	2.29

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANVS Annovis Bio	-$24.59M	-$2.16	N/A	N/A	N/A	N/A	-300.56%	-193.50%	8/13/2025 (Estimated)
CRGX CARGO Therapeutics	-$167.50M	-$4.62	N/A	N/A	N/A	N/A	-45.93%	-39.58%	8/11/2025 (Estimated)
MNPR Monopar Therapeutics	-$15.59M	-$3.48	N/A	N/A	N/A	N/A	-55.39%	-51.53%	8/8/2025 (Estimated)
YMAB Y-mAbs Therapeutics	-$29.67M	-$0.64	N/A	N/A	N/A	-31.84%	-30.59%	-22.70%	8/11/2025 (Estimated)

Latest ANVS, MNPR, YMAB, and CRGX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	ANVS Annovis Bio	-$0.47	-$0.32	+$0.15	-$0.32	N/A	N/A
5/13/2025	Q1 2025	MNPR Monopar Therapeutics	-$0.65	-$0.38	+$0.27	-$0.38	N/A	N/A
5/13/2025	Q1 2025	YMAB Y-mAbs Therapeutics	-$0.22	-$0.12	+$0.10	-$0.12	$19.97 million	$20.90 million
3/31/2025	Q4 2024	MNPR Monopar Therapeutics	-$0.36	-$2.23	-$1.87	-$2.23	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANVS Annovis Bio	N/A	N/A	N/A	N/A	N/A
CRGX CARGO Therapeutics	N/A	N/A	N/A	N/A	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	N/A
YMAB Y-mAbs Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANVS Annovis Bio	N/A	10.68	10.68
CRGX CARGO Therapeutics	N/A	6.30	6.30
MNPR Monopar Therapeutics	N/A	36.91	36.91
YMAB Y-mAbs Therapeutics	N/A	4.77	4.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANVS Annovis Bio	15.83%
CRGX CARGO Therapeutics	93.16%
MNPR Monopar Therapeutics	1.83%
YMAB Y-mAbs Therapeutics	70.85%

Insider Ownership

Company	Insider Ownership
ANVS Annovis Bio	20.80%
CRGX CARGO Therapeutics	2.92%
MNPR Monopar Therapeutics	20.50%
YMAB Y-mAbs Therapeutics	19.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANVS Annovis Bio	3	19.49 million	15.43 million	Optionable
CRGX CARGO Therapeutics	116	46.11 million	44.76 million	N/A
MNPR Monopar Therapeutics	10	6.12 million	4.86 million	Not Optionable
YMAB Y-mAbs Therapeutics	150	45.28 million	36.36 million	Optionable

ANVS, MNPR, YMAB, and CRGX Headlines

Recent News About These Companies

Y mAbs Therapeutics News (YMAB) - Investing.com

June 26 at 3:52 PM | investing.com

We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate

June 11, 2025 | finance.yahoo.com

Wesbanco Bank Inc. Acquires Shares of 55,000 Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

June 11, 2025 | marketbeat.com

Cantor Fitzgerald Comments on YMAB FY2026 Earnings

June 10, 2025 | marketbeat.com

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Rating of "Moderate Buy" from Analysts

June 9, 2025 | marketbeat.com

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Acquired by Bank of America Corp DE

June 8, 2025 | marketbeat.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Lowered to $15.00 at Oppenheimer

May 30, 2025 | marketbeat.com

Wedbush Reiterates Outperform Rating for Y-mAbs Therapeutics (NASDAQ:YMAB)

May 29, 2025 | marketbeat.com

Wedbush Reaffirms "Outperform" Rating for Y-mAbs Therapeutics (NASDAQ:YMAB)

May 29, 2025 | marketbeat.com

Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline

May 28, 2025 | globenewswire.com

Infinitum Asset Management LLC Purchases New Stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

May 28, 2025 | marketbeat.com

Y-mAbs Therapeutics, Inc. (YMAB) Unveils Promising Cancer Trial Data at ANR 2025

May 26, 2025 | insidermonkey.com

Y-mAbs Therapeutics Presents GD2-SADA Data at Advances in Neuroblastoma Research Meeting

May 26, 2025 | quiverquant.comQ

Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting

May 26, 2025 | globenewswire.com

Y-mAbs Therapeutics’ SWOT analysis: antibody innovator’s stock faces growth hurdles

May 24, 2025 | investing.com

Truist Financial Sticks to Its Buy Rating for Y-Mabs Therapeutics (YMAB)

May 16, 2025 | theglobeandmail.com

Y-mAbs Therapeutics Inc (YMAB) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges

May 14, 2025 | finance.yahoo.com

Y-mAbs Therapeutics, Inc.: Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments

May 13, 2025 | finanznachrichten.de

Y-mAbs Therapeutics, Inc. (YMAB) Q1 2025 Earnings Call Transcript

May 13, 2025 | seekingalpha.com

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates

May 13, 2025 | zacks.com

Y-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025

May 13, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANVS, MNPR, YMAB, and CRGX Company Descriptions

Annovis Bio NYSE:ANVS

$2.10 -0.07 (-3.41%)

Closing price 06/27/2025 03:59 PM Eastern

Extended Trading

$2.13 +0.03 (+1.62%)

As of 06/27/2025 07:15 PM Eastern

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

CARGO Therapeutics NASDAQ:CRGX

$4.19 -0.03 (-0.71%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$4.19 0.00 (0.00%)

As of 06/27/2025 05:59 PM Eastern

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.

Monopar Therapeutics NASDAQ:MNPR

$33.60 -1.41 (-4.03%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$33.59 -0.01 (-0.03%)

As of 06/27/2025 05:50 PM Eastern

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Y-mAbs Therapeutics NASDAQ:YMAB

$4.70 -0.10 (-2.08%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$4.70 0.00 (0.00%)

As of 06/27/2025 04:34 PM Eastern

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time